Jensen P, Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P, Simonsen S, et al.
Journal of the American Academy of Dermatology. Date of publication 1999 Feb 1;volume 40(2 Pt 1):177-86.
1. J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):177-86.
Skin cancer in kidney and heart transplant recipients and different long-term
immunosuppressive therapy regimens.
Jensen P(1), Hansen S, Møller B, Leivestad T, Pfeffer P, Geiran O, Fauchald P,
Simonsen S.
Author information:
(1)Department of Dermatology, Rikshospitalet, University of Oslo, Norway.
Comment in
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307.
BACKGROUND: Nonmelanoma skin cancer occurs frequently in organ transplant
recipients, but the relative importance of different immunosuppressive therapy
regimens is unclear.
OBJECTIVE: We studied the risk of skin cancer in the complete, single-center
Norwegian cohort of kidney and heart transplant recipients (n = 2561).
METHODS: We determined cancer risk estimation by means of standardized incidence
ratios and multivariate Cox regression.
RESULTS: Transplant recipients had an increased risk of cutaneous squamous cell
carcinoma (SCC) (65-fold), malignant melanoma (3-fold), and Kaposi's sarcoma
(84-fold), and of lip SCC (20-fold), compared with the general population. After
adjustment for age, kidney transplant recipients receiving cyclosporine,
azathioprine, and prednisolone had a significantly (2.8 times) higher risk of
cutaneous SCC relative to those receiving azathioprine and prednisolone. After
adjustment for age and type of immunosuppressive regimen, heart transplant
recipients had a significantly (2.9 times) higher risk than kidney transplant
recipients.
CONCLUSION: The risk of cutaneous SCC, malignant melanoma, Kaposi's sarcoma, and
lip SCC is increased in kidney and heart transplant recipients. The risk of
posttransplant cutaneous SCC is related to the degree of immunosuppression caused
by long-term immunosuppressive therapy.
DOI: 10.1016/s0190-9622(99)70185-4
PMID: 10025742 [Indexed for MEDLINE]
